Brian E. Zimmerman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brian E. Zimmerman has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
J.T. Cessna
Physical Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899-8462 USA
5 shared publicationsD.E. Bergeron
3 shared publicationsG Ratel
International Bureau of Weights and Measures
2 shared publicationsJeffrey T. Cessna
Physical Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland
2 shared publicationsL. Mo
2 shared publicationsR. Fitzgerald
Physical Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899-8462 USA
2 shared publications
Latest Publications
- 19 November 2026
- Published by Elsevier in Applied Radiation and Isotopes
Gamma ray emission intensity and half-life measurements for 89Zr
- 19 November 2026
- Published by Elsevier in Applied Radiation and Isotopes
Gamma ray emission intensity and half-life measurements for 89Zr
- 6 October 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 226, 112239
Nuclear decay data evaluation for 212Pb
- 6 October 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 226, 112239
Nuclear decay data evaluation for 212Pb
- Open Access
- 10 April 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 224, 111827
Needs for radionuclide metrology in the use of alpha-emitters for radionuclide-based therapy: Summary of an International Workshop
- 10 April 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 224, 111827
Open AccessNeeds for radionuclide metrology in the use of alpha-emitters for radionuclide-based therapy: Summary of an International Workshop
- 17 May 2024
- Published by National Institute of Standards and Technology (NIST)
Early electroscopes at the National Bureau of Standards
This report describes the use of five electroscopes used as national standards for radioactivity for the United States during the early 20th century. This set of instruments were used for the calibration of thousands of radium-226 sources used in medical therapy in the US from 1913 to 1989. The provenance of these instruments is recorded here to aid historians and curators in preservation of knowledge and artifacts of early radioactivity measurements in the United States.
- 17 May 2024
- Published by National Institute of Standards and Technology (NIST)
Early electroscopes at the National Bureau of Standards
This report describes the use of five electroscopes used as national standards for radioactivity for the United States during the early 20th century. This set of instruments were used for the calibration of thousands of radium-226 sources used in medical therapy in the US from 1913 to 1989. The provenance of these instruments is recorded here to aid historians and curators in preservation of knowledge and artifacts of early radioactivity measurements in the United States.
- 23 February 2024
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 207, 111230
A new evaluation of the decay data for 166Ho
- 23 February 2024
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 207, 111230
A new evaluation of the decay data for 166Ho
- 8 December 2020
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 27 (41) , 7003-7031
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage. Recent clinical studies provide compelling evidence that alpha-TRT has the potential to deliver a significantly more potent anti-cancer effect compared with beta-TRT. Generator-produced 212Pb (which decays to alpha emitters 212Bi and 212Po) is a particularly promising radionuclide for receptor-targeted alpha-particle therapy. A second attractive feature that distinguishes 212Pb alpha-TRT from other available radionuclides is the possibility to employ elementallymatched isotope 203Pb as an imaging surrogate in place of the therapeutic radionuclide. As direct non-invasive measurement of alpha-particle emissions cannot be conducted using current medical scanner technology, the imaging surrogate allows for a pharmacologically-inactive determination of the pharmacokinetics and biodistribution of TRT candidate ligands in advance of treatment. Thus, elementally-matched 203Pb labeled radiopharmaceuticals can be used to identify patients who may benefit from 212Pb alpha-TRT and apply appropriate dosimetry and treatment planning in advance of the therapy. In this review, we provide a brief history on the use of these isotopes for cancer therapy; describe the decay and chemical characteristics of 203/212Pb for their use in cancer theranostics and methodologies applied for production and purification of these isotopes for radiopharmaceutical production. In addition, a medical physics and dosimetry perspective is provided that highlights the potential of 212Pb for alpha-TRT and the expected safety for 203Pb surrogate imaging. Recent and current preclinical and clinical studies are presented. The sum of the findings herein and observations presented provide evidence that the 203Pb/212Pb theranostic pair has a promising future for use in radiopharmaceutical theranostic therapies for cancer.
- 8 December 2020
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 27 (41) , 7003-7031
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage. Recent clinical studies provide compelling evidence that alpha-TRT has the potential to deliver a significantly more potent anti-cancer effect compared with beta-TRT. Generator-produced 212Pb (which decays to alpha emitters 212Bi and 212Po) is a particularly promising radionuclide for receptor-targeted alpha-particle therapy. A second attractive feature that distinguishes 212Pb alpha-TRT from other available radionuclides is the possibility to employ elementallymatched isotope 203Pb as an imaging surrogate in place of the therapeutic radionuclide. As direct non-invasive measurement of alpha-particle emissions cannot be conducted using current medical scanner technology, the imaging surrogate allows for a pharmacologically-inactive determination of the pharmacokinetics and biodistribution of TRT candidate ligands in advance of treatment. Thus, elementally-matched 203Pb labeled radiopharmaceuticals can be used to identify patients who may benefit from 212Pb alpha-TRT and apply appropriate dosimetry and treatment planning in advance of the therapy. In this review, we provide a brief history on the use of these isotopes for cancer therapy; describe the decay and chemical characteristics of 203/212Pb for their use in cancer theranostics and methodologies applied for production and purification of these isotopes for radiopharmaceutical production. In addition, a medical physics and dosimetry perspective is provided that highlights the potential of 212Pb for alpha-TRT and the expected safety for 203Pb surrogate imaging. Recent and current preclinical and clinical studies are presented. The sum of the findings herein and observations presented provide evidence that the 203Pb/212Pb theranostic pair has a promising future for use in radiopharmaceutical theranostic therapies for cancer.
- 1 April 2018
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 134, 68-73
Assessing the absolute quantitative accuracy of Positron Emission Tomography for Cu-64 using traceable calibrated phantoms
- 1 April 2018
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 134, 68-73
Assessing the absolute quantitative accuracy of Positron Emission Tomography for Cu-64 using traceable calibrated phantoms
- 1 April 2018
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 134, 433-438
Decay data for the positron emission tomography imaging radionuclide 124 I: A DDEP evaluation
- 1 April 2018
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 134, 433-438
Decay data for the positron emission tomography imaging radionuclide 124 I: A DDEP evaluation
- 2 September 2017
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 314 (2) , 605-609
Correlation in the application of the triple-to-double coincidence ratio method with unequal photomultiplier tube efficiencies
- 2 September 2017
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 314 (2) , 605-609
Correlation in the application of the triple-to-double coincidence ratio method with unequal photomultiplier tube efficiencies
- Open Access
- 1 June 2017
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 27 (2) , 98-112
Multi-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study
- 1 June 2017
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 27 (2) , 98-112
Open AccessMulti-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study